{"type":"trials","record":{"id":41937,"source_id":"clinicaltrials-gov","external_id":"NCT03939767","title":"Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","brief_summary":"In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Bayer","enrollment":1563,"countries":["Argentina","Australia","Belgium","Canada","China","Colombia","Denmark","France","Ireland","Italy","Norway","South Korea","Spain","Sweden","Switzerland","Thailand","United Kingdom"],"start_date":"2019-05-12","completion_date":"2023-10-17","last_update_date":"2024-09-20","source_url":"https://clinicaltrials.gov/study/NCT03939767","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"XTEND","age_range":"50 Years","comparator":null,"organization":"Bayer","interventions":["Aflibercept (Eylea, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["The change in BCVA (best corrected visual acuity) — Baseline to 12 months","The change in BCVA — Baseline to 24 and 36 months","The change in BCVA by intended treatment regimen — Baseline to 12, 24 and 36 months","The proportion of patients (eyes) gaining or losing a visual acuity compared to baseline — Baseline at 12, 24 and 36 mo…","The proportion of patients (eyes) achieving a Snellen equivalent of 20/40 or better (approximately 73 ETDRS letters) —…","The changes in central retinal thickness (CRT) — Baseline to 12, 24 and 36 months","The number of injections — Baseline to 12, 24 and 36 months","The distribution of the intervals between injections — Up to 36 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Aflibercept (Eylea, BAY86-5321)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03939767","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-05-12 to 2023-10-17","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.895Z","intervention":["Aflibercept (Eylea, BAY86-5321)"],"participants":1563,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The change in BCVA (best corrected visual acuity) — Baseline to 12 months","The change in BCVA — Baseline to 24 and 36 months","The change in BCVA by intended treatment regimen — Baseline to 12, 24 and 36 months","The proportion of patients (eyes) gaining or losing a visual acuity compared to baseline — Baseline at 12, 24 and 36 mo…","The proportion of patients (eyes) achieving a Snellen equivalent of 20/40 or better (approximately 73 ETDRS letters) —…","The changes in central retinal thickness (CRT) — Baseline to 12, 24 and 36 months","The number of injections — Baseline to 12, 24 and 36 months","The distribution of the intervals between injections — Up to 36 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41937","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}